Metraipolis › archive › dc_804fde437215
OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress — Europe PMC PMID:41561762
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41561762
- DOI
- 10.3389/fonc.2025.1730620
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T01:53:15.097Z
- SHA-256 of the archived text
af337423b1f997ab985341ed5128f3b88217e666639eb5ceec12174d9921db0b- Stable URL of this page
https://metraipolis.com/documento/dc_804fde437215
How to cite
OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress — Europe PMC PMID:41561762 — Europe PMC (en), https://europepmc.org/article/MED/41561762 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_804fde437215 (Metraipolis archive dc_804fde437215, sha256 af337423b1f997ab985341ed5128f3b88217e666639eb5ceec12174d9921db0b)
BibTeX
@misc{dc804fde437215,
title = {OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress — Europe PMC PMID:41561762},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41561762},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_804fde437215; sha256 af337423b1f997ab985341ed5128f3b88217e666639eb5ceec12174d9921db0b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41561762. Agents can read the archived copy with the MCP tool read_document.